Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:02 PM
Ignite Modification Date:
2025-12-24 @ 10:02 PM
NCT ID:
NCT00110032
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed and/or clinical and imaging evidence of a de novo mass that is likely to be a brain tumor
* Amenable to debulking surgery or surgical resection or biopsy as standard initial therapy for the tumor
* Performance status - Karnofsky 70-100%
* At least 3 months
* WBC count ≥ 2,000/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Bilirubin \< 1.2 mg/dL
* Creatinine \< 1.3 mg/dL
* No symptomatic congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia
* No other significant cardiac condition that would preclude study participation
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 1 month after study participation
* Weight ≤ 130 kg
* No peripheral neuropathy ≥ grade 3
* No history of allergic reaction attributed to metronidazole
* No other uncontrolled illness
* No psychiatric illness or social situation that would preclude study compliance
* No other medical condition that would preclude study participation
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00110032
Study Brief:
Protocol Section:
NCT00110032